Galeterone

Galeterone

Clinical data
Routes of administration	Oral
Identifiers
IUPAC name 17-(1H-benzimidazol-1-yl)androsta-5,16-dien-3β-ol
CAS Number	851983-85-2
PubChem (CID)	11188409
ChemSpider	9363493
UNII	WA33E149SW
KEGG	D10125
Chemical and physical data
Formula	C26H32N2O
Molar mass	388.25
3D model (Jmol)	Interactive image
SMILES C[C@]12CC[C@@H](CC1=CC[C@@H]3[C@@H]2CC[C@]4([C@H]3CC=C4N5C=NC6=CC=CC=C65)C)O
InChI InChI=1S/C26H32N2O/c1-25-13-11-18(29)15-17(25)7-8-19-20-9-10-24(26(20,2)14-12-21(19)25)28-16-27-22-5-3-4-6-23(22)28/h3-7,10,16,18-21,29H,8-9,11-15H2,1-2H3/t18-,19-,20-,21-,25-,26-/m0/s1 Key:PAFKTGFSEFKSQG-PAASFTFBSA-N

Galeterone (TOK-001 or VN/124-1) is a novel steroidal antiandrogen under development by Tokai Pharmaceuticals for the treatment of prostate cancer. It possesses a unique dual mechanism of action, acting as both an androgen receptor antagonist and an inhibitor of CYP17A1, an enzyme required for the biosynthesis of the androgens.^[1] It shows selectivity for 17,20-lyase over 17-hydroxylase.^[2]

Galeterone was being compared to enzalutamide in a phase III clinical trial (ARMOR3-SV) for AR-V7-expressing metastatic castration-resistant prostate cancer.^[3][4] Tokai announced the discontinuation of ARMOR3-SV on July 26, 2016, after a data monitoring committee determined that the trial was unlikely to meet its endpoint.^[5] On August 22, 2016, the company announced the discontinuation of their phase II expansion (ARMOR2) as well.^[6]

See also

• Abiraterone acetate
• Enzalutamide
• Apalutamide
• Darolutamide
• Orteronel
• Seviteronel
• EPI-001

References

1. Brawer MK (2008). "New treatments for castration-resistant prostate cancer: highlights from the 44th annual meeting of the american society of clinical oncology, may 30-june 3, 2008, chicago, IL". Rev Urol. 10 (4): 294–6. PMC 2615106. PMID 19145273.
2. Yin L, Hu Q (2014). "CYP17 inhibitors--abiraterone, C17,20-lyase inhibitors and multi-targeting agents". Nat Rev Urol. 11 (1): 32–42. doi:10.1038/nrurol.2013.274. PMID 24276076.
3. "A Study of Galeterone Compared to Enzalutamide In Men Expressing Androgen Receptor Splice Variant-7 mRNA (AR-V7) Metastatic CRPC - Full Text View - ClinicalTrials.gov". clinicaltrials.gov. Retrieved 2016-02-27.
4. Silberstein, John L.; Taylor, Maritza N.; Antonarakis, Emmanuel S. (2016-04-01). "Novel Insights into Molecular Indicators of Response and Resistance to Modern Androgen-Axis Therapies in Prostate Cancer". Current Urology Reports. 17 (4): 29. doi:10.1007/s11934-016-0584-4. ISSN 1534-6285. PMC 4888068. PMID 26902623.
5. http://www.businesswire.com/news/home/20160726005553/en/Tokai-Pharmaceuticals-Announces-Clinical-Update
6. http://seekingalpha.com/news/3204773-tokai-pharma-flux-lead-product-candidate-galeterone-enrollment-mid-stage-prostate-cancer